Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

Resolutions of Modulight Corporation’s Annual General Meeting and Inaugural Meeting of the Board of Directors on 2 May 2025

Modulight

Modulight Corporation | Company Release | May 02, 2025 at 15:30:00 EEST

The Annual General Meeting of Modulight Corporation was held on 2 May 2025 at 1 p.m. (Finnish time) at Korkeakoulunkatu 7, 33720 Tampere. Shareholders and their proxy representatives could participate in the Annual General Meeting and exercise their rights both by voting and presenting questions in advance and by exercising their voting and speaking rights on-site at the meeting.

The minutes of the General Meeting containing the full resolutions in Finnish and its unofficial English translation will be available on Modulight Corporation’s website https://modulight.com/agm2025/ on 16 May 2025 at the latest.

Adoption of the financial statements
The Annual General Meeting adopted the company’s financial statements, including consolidated financial statements, for the financial period ended on 31 December 2024.

The Annual General Meeting approved the Board of Directors’ proposal that the result for the financial year 2024, amounting to EUR -6,079 thousand, be transferred to the profit/loss account and that no dividend be distributed based on the balance sheet adopted for the financial year 2024.

Resolution on discharge from liability
The Annual General Meeting resolved to discharge the members of the Board of Directors and the CEO Seppo Orsila from liability for the financial period of 1 January–31 December 2024.

Remuneration report for Governing Bodies 2024
The Annual General Meeting resolved to adopt the Remuneration Report for the Governing Bodies.

Remuneration of the members of the Board of Directors
The Annual General Meeting resolved in accordance with the proposal of the Shareholders’ Nomination Board that the Chair of the Board be paid EUR 5,000 per month and each Board Member EUR 2,500 per month in remuneration. The remuneration may be paid to the members of the Board of Directors in company shares and in cash. In addition, travel expenses of all Board Members be reimbursed against receipt in accordance with the company’s travel policy.

The number of members of the Board of Directors
The Annual General Meeting resolved in accordance with the proposal of the Shareholders’ Nomination Board that the number of the members of the Board of Directors shall be four (4).

Composition of the Board of Directors
The Annual General Meeting re-elected the following persons as members of the Board of Directors in accordance with the proposal of the Shareholders’ Nomination Board: Anne Koutonen, Timur Kärki, Jyrki Liljeroos and Seppo Orsila. Anne Koutonen was elected as the Chair of the Board.

Remuneration of the auditor
The Annual General Meeting resolved that the auditor’s remuneration is paid in accordance with an invoice approved by the company.

Election of the auditor
Moore Idman Oy was elected as the company’s auditor for a term of office expiring upon the closing of the next Annual General Meeting. Moore Idman Oy has announced that Jussi Savio, APA, would act the auditor with principal responsibility.

Authorising the Board of Directors to decide on the repurchase of the company’s own shares and/or accepting them as a pledge
The Annual General Meeting decided to authorise the Board of Directors to decide upon the acquisition of a maximum of 4,261,693 of the company’s own shares in one or more tranches using the company’s unrestricted equity and/or accepting the same number of the company’s own shares as a pledge, in one or more tranches. The maximum total of shares that will be acquired and/or accepted as a pledge corresponds to approximately 10% of all shares in the company as of the date of the notice. However, the company cannot, together with its subsidiaries, own or accept as a pledge altogether more than 10% of its all shares at any point in time.

The shares will be acquired otherwise than in proportion to the holdings of the shareholders via public trading arranged by Nasdaq Helsinki Ltd at the market price that applies on the date of the acquisition or otherwise at a price formed on the market. Shares can be acquired and/or accepted as a pledge e.g., in order to execute a transaction or implement share-based incentive schemes or for other purposes as decided by the Board of Directors or otherwise for the purposes of further assignation, retention or cancellation. The Board of Directors is authorised to decide on all other terms and conditions that will apply to the acquisition and/or acceptance as a pledge of the company’s own shares.

The authorisation is valid until the closing of the next Annual General Meeting, yet no longer than until 30 June 2026.

Authorising the Board of Directors to decide on a share issue as well as the issuance of option rights and other special rights entitling to shares
The Annual General Meeting decided to authorise the Board of Directors to resolve on the issuance of shares as well as the issuance of option rights and other special rights entitling to shares referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act, in one or more tranches, either against payment or without payment.

The number of shares to be issued, including the shares received on the basis of the option rights and other special rights, may not exceed 4,261,693 shares, which amounts to approximately 10% of all shares in the company as of the date of the notice. The Board of Directors may decide to either issue new shares or to assign company shares that are held by the company.

The authorisation entitles the Board of Directors to decide on all terms and conditions that will apply to the share issue and to the issuance of option rights or other special rights entitling to shares, including the right to derogate from the shareholders’ pre-emptive subscription right. The shares can be used as consideration in transactions, as part of the company’s incentive schemes or for other purposes as decided by the Board of Directors.

The authorisation remains in force until the closing of the next Annual General Meeting, yet no longer than until 30 June 2026. This authorisation will revoke any previous unused authorisations to decide on a share issue and the issuance of option rights or other special rights entitling to shares.

Resolutions of the Inaugural Meeting of the Board of Directors
Appointed by the Annual General Meeting, the Board of Directors held its inaugural meeting immediately after the Annual General Meeting. At the meeting, the Board of Directors elected the members of its Remuneration Committee.

Anne Koutonen, Timur Kärki and Jyrki Liljeroos were elected as members of the Remuneration Committee of the Board of Directors.

The Board of Directors has evaluated that all of its members are independent of the company and its significant shareholders with the exception of Seppo Orsila, who is dependent of the company and its significant shareholders. Therefore, the Board of Directors of Modulight Corporation meets the requirements of the Recommendation 10 (Independence of Directors) of the Finnish Corporate Governance Code issued by the Finnish Securities Market Association.

MODULIGHT CORPORATION

For further information, please contact:


CEO Seppo Orsila, m. +358 40 830 4671

IR Ulla Haapanen, m. +358 40 830 4676
Email: ir@modulight.com

Certified adviser: Sisu Partners Oy, m. +358 40 555 4727
 
modulight.com
@modulight

Modulight in brief


Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company’s products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland.

Follow Modulight: modulight.com | X | LinkedIn | Facebook | YouTube | Instagram | #killcancer #laserfamily

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.